Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Vannetzel

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of the National Cancer Institute|November 2, 1994
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trialF A Lévi, R Zidani, J M Vannetzel, et al.
Cancer|November 1, 1985
A prospective study of detorubicin in malignant mesotheliomaN Colbert, J M Vannetzel, V Izrael, et al.
Anti-Cancer Drugs|December 13, 1997
Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancerP Soulié, L Trandafir, A Taamma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensityF Lévi, M Benavides, C Chevelle, et al.
Clinical and Experimental Immunology|February 1, 1988
Circadian rhythms in circulating T lymphocyte subtypes and plasma testosterone, total and free cortisol in five healthy menF A Lévi, C Canon, Y Touitou, et al.
The Annals of Thoracic Surgery|April 1, 1994
Extended operations after induction therapy for stage IIIb (T4) non-small cell lung cancerP Macchiarini, A R Chapelier, I Monnet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancerS G Taylor, A K Murthy, J M Vannetzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patientsJ P Droz, X Muracciole, N Mottet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2003
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancerG Ganem, M Tubiana-Hulin, P Fumoleau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patientsL Zelek, P Cottu, M Tubiana-Hulin, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of the National Cancer Institute|November 2, 1994
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trialF A Lévi, R Zidani, J M Vannetzel, et al.
Cancer|November 1, 1985
A prospective study of detorubicin in malignant mesotheliomaN Colbert, J M Vannetzel, V Izrael, et al.
Anti-Cancer Drugs|December 13, 1997
Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancerP Soulié, L Trandafir, A Taamma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1990
Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensityF Lévi, M Benavides, C Chevelle, et al.
Clinical and Experimental Immunology|February 1, 1988
Circadian rhythms in circulating T lymphocyte subtypes and plasma testosterone, total and free cortisol in five healthy menF A Lévi, C Canon, Y Touitou, et al.
The Annals of Thoracic Surgery|April 1, 1994
Extended operations after induction therapy for stage IIIb (T4) non-small cell lung cancerP Macchiarini, A R Chapelier, I Monnet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancerS G Taylor, A K Murthy, J M Vannetzel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patientsJ P Droz, X Muracciole, N Mottet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 29, 2003
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancerG Ganem, M Tubiana-Hulin, P Fumoleau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patientsL Zelek, P Cottu, M Tubiana-Hulin, et al.
Pageof 3